首页> 美国卫生研究院文献>BMJ Open Diabetes Research Care >Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study

【2h】

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study

机译：在每天两次从艾塞那肽切换到艾塞那肽的血糖治疗后进一步改善患有2型糖尿病患者的一次每周自动注射悬浮液：52周的持续时间 - Neo-1研究结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Investigate the effects of switching from two times per day exenatide to once-weekly exenatide administered by autoinjector (exenatide once-weekly suspension by autoinjector (QWS-AI)) or treatment with exenatide QWS-AI for 1 year.

机译：探讨通过每天两次切换到每周两次的效果，以自身灭口器（通过自身灭绝（QWS-AI）给药（Exenatide一次性悬浮）或用exenatide qws-ai治疗1年。

著录项

期刊名称 BMJ Open Diabetes Research Care
作者
Carol H Wysham; Julio Rosenstock; Marion L Vetter; Hui Wang; Elise Hardy; Nayyar Iqbal;
展开▼
作者单位

展开▼
年(卷),期 2020(8),1
年度 2020
页码 e000773
总页数 8
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词

机译：胰高血糖素肽-1（GLP-1）;2型糖尿病;血糖控制;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study (vol 19, pg 979, 2017) [J] . Gadde K. M., Vetter M. L., Iqbal N., Diabetes, obesity & metabolism . 2017,第9期

机译：Auto-Neo-2型糖尿病患者的AutoInject exenatide的疗效和安全性AutoInjeted exenatide每周悬浮或安慰剂与二甲双胍：持续时间 - Neo-2随机临床研究（Vol 19，PG 979,2017）
2. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study [J] . Gadde Kishore M., Vetter Marion L., Iqbal Nayyar, Diabetes, obesity & metabolism . 2017,第7期

机译：Auty 2型糖尿病患者的自动喷射卓脂酰胺和与二甲双胍的疗效和安慰剂的疗效和安全性：持续时间 - Neo-2随机临床研究
3. DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes [J] . Thomas Blevins, John Pullman, Jaret Malloy, The journal of clinical endocrinology and metabolism . 2011,第5期

机译：DURATION-5：2型糖尿病患者每周一次艾塞那肽与每日两次艾塞那肽相比，血糖控制得到更大改善
4. Classification of postprandial glycemic patterns in type 1 diabetes subjects under closed-loop control: an in silico study^* [C] . Corinna Schröder, José Luis Díez, Alejandro J. Laguna, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2019

机译：闭环控制下1型糖尿病患者餐后血糖模式分类：计算机研究^*
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Efficacy and safety of autoinjected exenatide once‐weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION‐NEO‐2 randomized clinical study [O] . Kishore M. Gadde, Marion L. Vetter, Nayyar Iqbal, -1

机译：自动注射艾塞那肽每周一次混悬液与西他列汀或安慰剂联合二甲双胍在2型糖尿病患者中的疗效和安全性：DURATION‐NEO-2随机临床研究
7. Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study [O] . Carol H Wysham, Julio Rosenstock, Marion L Vetter, 2020

机译：在每天两次从艾塞那肽切换到艾塞那肽的血糖治疗后进一步改善患有2型糖尿病患者的一次每周自动注射悬浮液：52周的持续时间 - Neo-1研究结果

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study

摘要

著录项

相似文献

相关主题

期刊订阅